Bone mineral homeostasis is achieved by the concerted actions of several hormones that control the circulating levels of calcium and phosphate, as well as directly affect osteoblastmediated mineralization and/or osteoclast-driven resorption (1, 2). Thus, skeletal mineral integrity is maintained by the availability of calcium and phosphate ions and by a coupled balance between the activities of osteoblasts and osteoclasts. Prominent among the endocrine factors that regulate bone mineral is the sterol, 1␣-25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ), 1 the active renal metabolite of vitamin D 3 (3). 1,25(OH) 2 D 3 functions via its nuclear vitamin D receptor (VDR) to induce intestinal calcium and phosphate absorption, as well as renal phosphate reabsorption, thereby preventing rickets/osteomalacia by ensuring adequate blood concentrations of these ions to facilitate bone mineralization (4, 5). Osteoblasts represent another target for 1,25(OH) 2 D 3 , where the sterol acts via VDR to induce bone remodeling proteins such as osteocalcin (6) and osteopontin (7), as well as the receptor activator of NF-B ligand (RANKL), which is a paracrine signal for osteoclastogenesis (8). Therefore, as a calcemic and phosphatemic hormone, 1,25(OH) 2 D 3 operates directly to resorb/remodel bone, and we show in the present communication that this sterol paradoxically also inhibits mineralization by cultured osteoblasts. The mechanism whereby 1,25(OH) 2 D 3 limits bone mineralization is herein characterized as the apparent up-regulation of a novel phosphaturic peptide(s), termed phosphatonin, via a repression in osteoblasts of the expression of a gene encoding a neutral endopeptidase PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) that is hypothesized to normally inactivate phosphatonin by proteolysis.
Bone mineral homeostasis is achieved by the concerted actions of several hormones that control the circulating levels of calcium and phosphate, as well as directly affect osteoblastmediated mineralization and/or osteoclast-driven resorption (1, 2) . Thus, skeletal mineral integrity is maintained by the availability of calcium and phosphate ions and by a coupled balance between the activities of osteoblasts and osteoclasts. Prominent among the endocrine factors that regulate bone mineral is the sterol, 1␣-25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ), 1 the active renal metabolite of vitamin D 3 (3) . 1,25(OH) 2 D 3 functions via its nuclear vitamin D receptor (VDR) to induce intestinal calcium and phosphate absorption, as well as renal phosphate reabsorption, thereby preventing rickets/osteomalacia by ensuring adequate blood concentrations of these ions to facilitate bone mineralization (4, 5) . Osteoblasts represent another target for 1,25(OH) 2 D 3 , where the sterol acts via VDR to induce bone remodeling proteins such as osteocalcin (6) and osteopontin (7) , as well as the receptor activator of NF-B ligand (RANKL), which is a paracrine signal for osteoclastogenesis (8) . Therefore, as a calcemic and phosphatemic hormone, 1,25(OH) 2 D 3 operates directly to resorb/remodel bone, and we show in the present communication that this sterol paradoxically also inhibits mineralization by cultured osteoblasts. The mechanism whereby 1,25(OH) 2 D 3 limits bone mineralization is herein characterized as the apparent up-regulation of a novel phosphaturic peptide(s), termed phosphatonin, via a repression in osteoblasts of the expression of a gene encoding a neutral endopeptidase PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) that is hypothesized to normally inactivate phosphatonin by proteolysis.
Phosphatonin, an uncharacterized phosphaturic hormone that may include in part FGF23 (9) , is an inhibitor of osteoblastic mineralization, which also blocks renal 25-OH-vitamin D 3 bioactivation to 1,25(OH) 2 D 3 , and elicits hypophosphatemia by repressing the renal type IIa sodium phosphate cotransporter (NaP i -IIa) (10) . The PHEX gene encodes an endopeptidase that is predominantly expressed in osteoblasts and osteocytes (11, 12) . Phenotypically, inactivating mutations in the PHEX gene results in vitamin D-resistant, X-linked hypophosphatemic rickets (X-linked hypophosphatemia; XLH) (11) . This familial disorder manifests as hypophosphatemia, low circulat-ing 1,25(OH) 2 D 3 levels for the prevailing blood phosphate, high serum alkaline phosphatase, and osteomalacia (13) . A theoretical model postulates that phosphatonin regulates P i reabsorption through changes in renal NaP i -IIa cotransporter expression. PHEX normally inactivates phosphatonin, limiting P i excretion; in XLH, the mutant PHEX fails to inactivate phosphatonin, resulting in phosphaturia and hypophosphatemia (10) . The defects in bone associated with XLH are not fully attributable to hypophosphatemia, and there is evidence for an intrinsic abnormality in the osteoblast (14) . This hypothesis is supported by the observation that osteoblasts from Hyp mice (the murine homologue of XLH, deficient in PHEX), fail to mineralize in media supporting mineralization of normal osteoblasts. Further, when co-cultured with Hyp osteoblasts, normal osteoblasts exhibit a significant decrease in mineralization (14) . Finally, targeted expression of PHEX in Hyp mice osteoblasts is not sufficient to rescue the Hyp phenotype (15, 16) . These observations highlight the significance of the PHEX endopeptidase gene product in promoting osteoblastic mineralization, presumably by inactivating the phosphatonin antimineralization peptide.
Regulation of PHEX both in vivo and in vitro by several hormones important for skeletal homeostasis has been reported. Up-regulation of PHEX expression was observed with IGF-I (17, 18) and growth hormone (GH) (18) treatment of laboratory rodents, and with glucocorticoid exposure of cultured cells (19) . Conversely, PHEX was found to be down-regulated by parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) in UMR-106 osteoblastic cells (20) . 1,25(OH) 2 D 3 downregulation of PHEX has been shown at the mRNA and protein levels in both cultured mouse osteoblasts (21) and more recently in 1,25(OH) 2 D 3 -treated rats (22) . In primary osteoblasts and MC3T3-E1 cells, 1,25(OH) 2 D 3 -mediated PHEX down-regulation was independent of the mineralization state of the cells (21) . Additionally, 1,25(OH) 2 D 3 has also been reported to decrease mineralization in osteoblasts grown in culture (21, 23) . Finally, an altered mineralization response to 1,25(OH) 2 D 3 was observed in osteoblasts isolated from Hyp mice compared with those isolated from normal mice (24) . These studies highlight the physiological relevance of PHEX in osteoblast function and point to the important effects of 1,25(OH) 2 D 3 on PHEX expression in these bone-mineralizing cells.
We have previously cloned ϳ3000 bp of the 5Ј-flanking region of the murine PHEX gene and have shown that it is sufficient to drive reporter gene expression in UMR-106 rat, osteoblast-like, osteosarcoma cells (25) . We thus undertook the current investigation to verify that 1,25(OH) 2 D 3 represses both PHEX expression and mineralization, and to determine the molecular mechanism by which 1,25(OH) 2 D 3 decreases PHEX expression. To this end, we examined the effect of 1,25(OH) 2 D 3 on PHEX mRNA levels in mice, and on the expression and stability of PHEX mRNA in UMR-106 cells. Reporter gene assays and electrophoretic mobility shift assays (EMSA) were used to identify and characterize the PHEX promoter region involved in 1,25(OH) 2 D 3 regulation of gene expression. Our results demonstrate a novel 1,25(OH) 2 D 3 transcriptional regulatory mechanism involving VDR-mediated repression of an unidentified transacting factor(s) that binds to a polyadenine element in the 5Ј-flanking region of the murine PHEX gene. Our data further indicate that this transfactor is required for optimal transcriptional initiation of the PHEX gene.
EXPERIMENTAL PROCEDURES
Experimental Animals-4 -5-week-old male C57BL/6 mice in groups of 3-4 were subcutaneously injected once with 1,25(OH) 2 D 3 (Sigma) at a dosage of 6 g/kg b.w. or with an equal volume of vehicle (1:4, ethanol:propylene glycol) (26) . Animals were supplied with food and water ad libitum. The mice were sacrificed 24 h after injection by CO 2 narcosis followed by cervical dislocation. Calvaria were removed, flash frozen in liquid nitrogen, and stored at Ϫ70°C.
Chemicals and Reagents-10ϫ TBE, 20ϫ SSC, 100 mM sodium pyruvate, 100ϫ antibiotic-antimycotic, restriction enzymes, Superscript II, 6% DNA retardation gels, dNTPs, random hexamers, TRIzol reagent, and T 4 DNA ligase were purchased from Invitrogen (Carlsbad, CA). DME high glucose medium and fetal bovine serum were from Irvine Scientific (Santa Ana, CA). [␣-
32 P]dATP and [␥-32 P]ATP were from PerkinElmer Life Sciences. Taq polymerase was from Continental Laboratory Products (San Diego, CA). DNA oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, IA). PHEX and 18 S Taqman primer/probe sets, and TaqMan universal PCR master mix were purchased from Applied Biosystems (Foster City, CA). Streptavidin MagneSphere Paramagnetic Particles (SA-PMP) and polynucleotide kinase were purchased from Promega (Madison, WI). Gels and reagents for SDS-PAGE were from Bio-Rad. All other reagents, unless otherwise indicated, were purchased from Fisher Scientific or Sigma.
Northern Blot Analyses-Total RNA was prepared from mouse calvaria or UMR-106 cells using TRIzol reagent according to the manufacturer's protocol. 10 g of total RNA were fractionated on a 1% formaldehyde gel and downward transferred to a Zeta-Probe GT nylon membrane (Bio-Rad). Antisense PHEX and GAPDH radiolabeled, single-stranded DNA probes were generated using the PCR EZ strip kit (Ambion; Austin, TX). The PHEX probe was synthesized using PHEX reverse primer 5Ј-TGTCATGTTCAGCTCGAGAG-3Ј, with a mouse PHEX cDNA template from ϩ816 bp to ϩ1443 bp (97% homology between mouse and rat) (GenBank TM accession number NM_011077), and [␣-
32 P]dATP. The GAPDH probe was synthesized using GAPDH reverse primer 5Ј-CAGTGAGCTTCCCGTTCA-3Ј, with a mouse GAPDH DNA template from ϩ1060 bp to ϩ1635 bp (GenBank TM accession AF106860), and [␣-
32 P]dATP. Membranes were hybridized with radiolabeled probe and washed as previously described (19) , and then exposed to x-ray film (Pierce) at Ϫ70°C. Resulting films were analyzed using a Bio-Rad GS-700 Imaging Densitometer with Quantity One software (Bio-Rad). PHEX hybridization band intensities were normalized for GAPDH hybridization band intensities on the same membrane. Experiments were repeated three times with different groups of mice or with cells grown at different times.
Real-time PCR-10 g of total RNA were treated with DNase I according to the DNA free kit protocol (Ambion). The resulting RNA was evaluated by agarose gel electrophoresis and concentrations were adjusted according to densitometric analysis of the 18 S rRNA band. 250 ng of DNase I-treated RNA were reverse-transcribed using Superscript II and random primers (Invitrogen; according to the manufacturer's protocol). Subsequently, 20-l PCR reactions were set up in 96-well plates containing 10 l of TaqMan universal PCR master mix, 1 l of TaqMan primer/probe set, 2 l of cDNA synthesis reaction (out of a 20-l total volume), and 7 l of molecular grade water. Reactions were run and analyzed on a Bio-Rad iCycler iQ Real-Time PCR detection system. Cycling parameters were determined, and resulting data were analyzed according to ABI protocols. Briefly, data were analyzed using the comparative Ct method as means of relative quantitation, normalized to an endogenous reference (18 S ribosomal RNA) and relative to a calibrator (normalized C T value obtained from vehicle-treated UMR-106 cells or mice) and expressed as 2 Ϫ⌬⌬C T according to Applied Biosystems User Bulletin 2: Rev B Relative Quantitation of Gene Expression.
Reporter Gene Constructs-Progressive promoter deletions, with the same 3Ј-ends, were generated between Ϫ1064 and Ϫ133 bp of the PHEX promoter (25) by PCR, and cloned into p␤Gal-Basic (Clontech; Palo Alto, CA) as previously described (25) . A poly(A) deletion construct was generated by two step PCR using primers with the polyadenine region deleted, forward 5Ј-CTTCGTCTTCCTGTTCCAGTCCAAACC-3Ј reverse 5Ј-GGTTTGGACTGGAACAGGAAGACGAAG-3Ј, as previously described (19) , and the resulting PCR product was cloned into p␤Gal-Basic. All promoter/reporter gene constructs were sequenced to confirm fidelity.
Cell Culture and Transient Transfection-Rat osteogenic sarcoma cells (UMR-106) were obtained from the American Type Culture Collection (ATCC CRL-1661) and were cultured in DME high glucose media containing 10% fetal bovine serum, 1 mM sodium pyruvate, and 1ϫ antibiotic-antimycotic at 37°C with 5% CO 2 . For analysis of endogenous PHEX gene expression, cells were seeded on 100-mm plates at 2 ϫ (27) was added to each reaction. Cell extracts were assayed for ␤-galactosidase activity using the Galacto-Star ␤-galactosidase reporter gene assay system (Tropix; Bedford, MA). Protein concentrations for each transfection were determined by BCA protein assay (Pierce). Promoter activity is expressed as ␤-galactosidase activity per microgram of protein. In each experiment, the results from three wells for 24-well plates or from two 100-mm plates were averaged and considered as n ϭ 1. Analysis of in vitro mineralization was performed as described by Hale et al. (28) . Briefly, cells were seeded at 3 ϫ 10 4 cells per well in 6-well plates and cultured as described above, supplemented with 10 mM ␤-glycerophosphate and 50 g/ml L-ascorbic acid. Three days after seeding, cells were treated with 10 Ϫ7 M 1,25(OH) 2 D 3 or vehicle. Media containing 1,25(OH) 2 D 3 or vehicle were changed every 48 h. After 24, 48, or 72 h of treatment, these media were replaced with media containing 1 g of calcein and incubated an additional 4 h. For analysis of bound calcein, cells were washed three times with calcium-magnesium-free phosphate-buffered saline, overlaid with 1 ml of phosphate-buffered saline, and fluorescence was read on a Fluorskan Ascent FL plate reader (Labsystems; Helsinki, Finland) (excitation 485 nm, emission 527 nm).
EMSA-Nuclear protein (N.P.) for EMSA was prepared from UMR-106 cells as previously described (29) . Double-stranded, synthetic oligonucleotides were end-labeled with [␥-
32 P]dATP. For each reaction, 50,000 dpm of probe were incubated at room temperature for 30 min with 2.5 g of nuclear protein, 4 l of 5ϫ binding buffer (125 mM HEPES, pH 7.9, 25 mM MgCl 2 , 0.5 mM dithiothreitol, 0.25% Nonidet P-40, 500 mM KCl, 20% Ficoll, 25 M ZnCl 2 ) (29), 1 g of poly(d(I-C)) (Sigma), and H 2 O to a final volume of 20 l. For competition studies, 100ϫ cold probe was also added to the reaction. For EMSA with purified human VDR (hVDR) and human retinoid X receptor ␣ (hRXR␣) (30) , 100 ng of hVDR and 100 ng of hRXR␣ were substituted for nuclear protein, and 1,25(OH) 2 D 3 was added to a final concentration of 10
Subsequently, 5 l of DNA loading buffer (0.25ϫ TBE, 60%; glycerol, 40%; bromphenol blue, 0.2% (w/v)) were added, and the reaction was loaded on a 6% DNA retardation gel (Invitrogen) and electrophoresed at 250 volts in 0.5ϫ TBE. Gels were dried and then exposed to x-ray film (Pierce) at Ϫ70°C. Oligonucleotides used for EMSAs are described below in Fig. 6 .
Southwestern Blot Analysis-Nuclear protein was prepared as described above for EMSA, and was fractioned on 7.5% Tris-glycine SDSpolyacrylamide gels and transferred to nitrocellulose membranes. Immobilized proteins were then renatured overnight at room temperature in 1ϫ EMSA buffer containing 5% nonfat, dried milk. Blots were then washed for 15 min three times with 1ϫ EMSA buffer with 5% milk. Blots were then incubated overnight at room temperature with rocking, in the presence of 1ϫ EMSA buffer containing 5% milk and 1 ϫ 10 7 dpm of 32 P end-labeled DNA probe. Following hybridization, blots were washed three times for 15 min in 1ϫ EMSA buffer and then exposed to x-ray film.
DNA Affinity Protein Enrichment-A probe corresponding to Ϫ134 to Ϫ85 bp of the PHEX promoter region was generated by annealing a 5Ј biotin-labeled Ϫ134/Ϫ85 GS oligonucleotide (see Fig. 6 ) with an unlabeled complementary oligonucleotide. 200 l of Streptavidin MagneSphere® Paramagnetic Particles (SA-PMPs) were separated from storage buffer in a magnetic field, and storage buffer was removed. SAPMPs were resuspended in 500 l of 1ϫ EMSA buffer. 10 nM biotinylated probe and 1 mg of bovine serum albumin were added to the SA-PMPs, and the reaction was incubated at room temperature with rotation for 1 h. 16 g of UMR-106 nuclear protein were then added to the reaction and incubated 1 h at room temperature with rotation. Following incubation, SA-PMPs were separated from supernatant in a magnetic field, the supernatant was removed, and SA-PMPs were resuspended in 1ϫ EMSA buffer. This washing procedure was repeated twice. After washing, SA-PMPs were resuspended in 30 l of Laemmli sample buffer containing ␤-mercaptoethanol, boiled for 5 min, and the supernatant was electrophoresed on a 7.5% Tris-glycine SDS-polyacrylamide gel. The gel was stained overnight with SYPRO Ruby (Molecular Probes; Eugene, OR) and subsequently destained for 30 min according to the manufacturer's protocol. Gels were then scanned to provide digital images (Bio-Rad FX Molecular Imager®).
Statistical Analysis-Statistical significance was determined by the Student's t test or analysis of variance followed by Fisher's PLSD, using the Statview software package version 4.53 (SAS Institute; Cary, NC). Data are expressed as means Ϯ S.E. 2 (Fig. 1, A and B) . Furthermore, real-time PCR analysis of the same RNA used for Northern blot analysis displayed virtually identical decreases in PHEX mRNA expression at 24, 48, and 72 h of 1,25(OH) 2 D 3 treatment (Fig. 1C) , i.e. significant repression at 24 h and a near maximal decrease at 48 h.
RESULTS

Repression of PHEX Expression and Inhibition of Mineralization by 1,25(OH)
The potential biological relevance of 1,25(OH) 2 D 3 down-regulation of PHEX in UMR-106 cells was investigated by assessing the effect of the sterol hormone on mineralization. As seen in Fig. 2 , the mineralization of cultured UMR-106 osteoblasts is dramatically attenuated by treatment of the cells with 10 Ϫ7 M 1,25(OH) 2 D 3 , to ϳ80% by 72 h. The temporal association between PHEX repression ( Fig. 1) and inhibition of mineralization at 24 -72 h by 1,25(OH) 2 D 3 ( Fig. 2) suggests, but does not prove, that the repression of PHEX endopeptidase activity results in higher effective concentrations of phosphatonin to in turn inhibit mineralization. Thus, UMR-106 cells are a biologically valid osteoblast model in which to investigate PHEX regulation, and we have previously shown that the murine PHEX promoter is active when transfected into these cells (25 (Fig. 1, B and C) . Furthermore, this in vivo decrease in PHEX mRNA expression is in agreement with the approximate 40% decrease in PHEX mRNA and protein expression reported by Brewer et al. (22) for 48 h, revealed a 50 -55% percent decrease in promoter activity with the Ϫ542/ ϩ104 and Ϫ133/ϩ104 promoter constructs (Fig. 4) . However, no effect on reporter gene activity was observed with 1,25(OH) 2 D 3 treatment of cells transfected with the Ϫ74/ϩ104 construct (Fig. 4) . These data suggest that a putative silencing element that mediates the effect of 1,25(OH) 2 D 3 resides between Ϫ134 and Ϫ74 of the murine PHEX promoter.
Nuclear VDR Mediates the Repression of the PHEX Proximal Promoter by 1,25(OH) 2 D 3 -To elucidate whether the decrease in
PHEX proximal promoter activity with 1,25(OH) 2 D 3 is mediated by the nuclear VDR, a dominant-negative point mutant of hVDR (DNVDR), namely E420A hVDR (27) , was overexpressed in UMR-106 cells. The E420A hVDR has a mutated helix-12 activation function-2 (AF-2); therefore it is incapable of attracting coactivators for transcriptional stimulation (27) . Transfection of 600 ng of DNVDR plasmid elicited a marked attenuation (54-fold to 16-fold) of 1,25(OH) 2 D 3 responsiveness with a human vitamin D 24-hydroxylase (24-OHase)-positive VDRE-luciferase reporter construct (Fig. 5A) . Overexpression of the E420A DNVDR suppressed basal transcription of PHEX to a level that was no longer repressible with addition of the 1,25(OH) 2 D 3 ligand (Fig. 5B) , rather than attenuating 1,25(OH) 2 D 3 -dependent activation (Fig.  5A ). This suggests that when overexpressed DNVDR is used to evaluate a repressive effect, it actually functions as a constitutive 1,25(OH) 2 D 3 -independent, repressor of basal transcription. Thus, the repressive effect of 1,25(OH) 2 D 3 on the PHEX gene appears to be mediated by VDR, either via a negative VDRE in the promoter between Ϫ134 and Ϫ74, or indirectly through a negative VDRE in a gene encoding a separate transfactor necessary for basal activity of the PHEX promoter. Since maximal repression by 1,25(OH) 2 D 3 was not observed until 48 h, the latter possibility seems more likely.
EMSA Analysis of the PHEX Promoter Region from Ϫ134 to Ϫ74 bp-Reporter gene analysis of the PHEX promoter revealed that a region between Ϫ134 and Ϫ74 was responsible for 1,25(OH) 2 D 3 down-regulation. Thus, we sought to determine if VDR/RXR heterodimers interacted directly with the Ϫ134 to Ϫ74 region. Visual inspection of this region, pictured in Fig. 6 , failed to identify sequences with similarity to known negative 1,25(OH) 2 D 3 response elements (nVDREs) (3). Nonetheless, to investigate the possibility that the VDR binds to this region, EMSA was conducted with two overlapping probes spanning the Ϫ134 to Ϫ74 bp region (i.e. Ϫ134/Ϫ85 and Ϫ102/Ϫ71, see Fig. 6 ), along with purified hVDR and its hRXR␣ heterodimeric protein partner. Gel shift analysis revealed no detectable binding of VDR/RXR to either PHEX probe, whereas strong binding was observed with a positive control oligonucleotide containing the mouse osteopontin (MOP) VDRE (data not shown) (31) . Therefore, unless VDR requires an unknown DNA-binding protein tether to associate with this region of the PHEX promoter, VDR-mediated repression of PHEX may be executed via an indirect mechanism.
To determine whether other nuclear proteins interact with this region of the PHEX promoter, EMSA was conducted using synthetic double-stranded oligonucleotides Ϫ134/-85 GS, and Ϫ102/Ϫ71 GS (Fig. 6 ), and N.P. obtained from UMR-106 cells. Incubation of the Ϫ134/Ϫ85 GS probe with N.P. revealed a single shifted band (Fig. 6A, lane 2) , whereas no N.P. binding was observed with the Ϫ102/Ϫ71 GS probe (data not shown).
Computer analysis of the Ϫ134/Ϫ85 GS probe region for putative transcription factor binding sites using Matinspector pro (www.genomatix.de/cgi-bin/matinspector_prof/mat_fam.pl), indicated putative binding sites for BCL6, STAT, and MEF2 (which overlap), as well as MYT1 (Fig. 6 ). To determine if the specific, shifted complex was the result of binding to one or more of these four predicted cis-elements, N.P. binding to the Ϫ134/Ϫ85 GS probe was competed with a 100-fold excess of cold probes with single mutations in these sites or mutations in all four of the predicted cis-elements (Fig. 6 ). These experiments revealed that mutations abolishing all four cis sites, singly and in combination, generated oligonucleotides in the Ϫ126 to Ϫ88 region that still competed the shifted band, indicating a lack of N.P. binding to these putative sites (Fig. 6A , lanes 4 -6) .
Further EMSAs with three overlapping competitor probes (Comp 1, Comp 2, Comp 3), spanning the Ϫ141 to Ϫ88 region, suggested partial competition by Comp 2 and Comp 3, but no competition with Comp 1 (Fig. 6A, lanes 7-9) . Comp 2 and Comp 3 each contain 10 A-T base pairs of the 17-base pair polyadenine stretch in the murine PHEX promoter (Fig. 6) . We therefore assessed directly if the poly(A) region bound N.P. from UMR-106 cells. EMSAs demonstrated that a 28-base pair poly(A) oligonucleotide probe was able to obliterate the shifted complex (Fig. 6A,  lane 10) . To confirm that this polyadenine stretch was the site of protein binding, the labeled Ϫ134/Ϫ85 GS probe was competed with excess nonradioactive Ϫ128/Ϫ85⌬(Ϫ116/Ϫ100) GS, in which the 17-bp poly(A) stretch was deleted. This oligonucleotide failed to compete the shifted complex (Fig. 6A, lane 11) , pinpointing the polyadenine stretch as the region of nuclear protein binding. Moreover, the mobility of a 32 P-labeled polyadenine probe retarded as a single band when incubated with UMR-106 N.P., whereas no shift was observed when labeled Ϫ128/ Ϫ85⌬(Ϫ116/Ϫ100) GS was used as a probe (data not shown). Therefore, we conclude that an apparently unique nuclear protein(s) in UMR-106 osteoblasts binds to the 17 A-T bp element in the proximal PHEX promoter. Fig. 6C show that inclusion of excess liganded VDR-RXR did not result in a decrease in binding to the PHEX poly(A) region. This suggests that the decrease in binding is likely not the result of direct negative interaction of liganded VDR/RXR with the nuclear protein that binds to the polyadenine region of the PHEX promoter, and points instead to indirect repression of the poly(A)-binding protein.
1,25(OH) 2 D 3 Treatment of UMR-106 Cells Reduces the Association of Nuclear Protein with the Poly(A) Element in the PHEX
Southwestern Blot Analysis of the Protein(s) Interacting with the Poly(A) Region of the PHEX Promoter-Southwestern blot
analysis was next performed to determine the approximate molecular mass of the protein(s) that binds to the poly(A) stretch from Ϫ116 to Ϫ100 bp of the murine PHEX promoter. This experiment revealed that the 32 P-labeled Ϫ134/Ϫ85 GS probe bound to a protein of approximate molecular mass of 110 kDa, which was not observed with addition of 100ϫ excess cold probe to the hybridization reaction (Fig. 7A) . Furthermore, a dramatic decrease in binding was found when the Ϫ134/Ϫ85 GS probe was hybridized to nuclear protein extracted from 10 Ϫ7 M 1,25(OH) 2 D 3 treated UMR-106 cells (Fig. 7A) . Membranes were stained with Ponceau S to confirm equal protein loading prior to hybridization with the DNA probe. The results shown in Fig. 7A To further investigate the protein(s) that interacts with the poly(A) region, we incubated a biotin labeled Ϫ134/Ϫ85 GS probe with N.P. under the same conditions used for EMSA, then separated the probe/protein complex from the remaining N.P. with SA-PMP. Although SDS-PAGE and subsequent Sypro Ruby staining of the gel revealed nonspecific binding of protein to the SA-PMP, an enriched band was observed at ϳ110 kDa (Fig. 7B) . Furthermore, this band was not present when an excess of non-biotin-labeled Ϫ134/Ϫ85 GS probe was added to the binding reaction (Fig. 7B ). This affinity purification independently confirms that the 110 kDa poly(A)-binding protein from UMR-106 cells associates specifically with the poly(A) element in the PHEX promoter, and extensions of this procedure should permit the eventual isolation and identification of this transfactor.
Functional Analysis of the Poly(A) Region of PHEX Promoter-As a final test of the relevance of the 110 kDa nuclear protein to PHEX transcription and to examine whether its poly(A) cis element docking site is involved in the 1,25(OH) 2 D 3 -dependent regulation of PHEX promoter activity, a promoter/ reporter construct was created with the 17 base polyadenine region deleted (Ϫ133/ϩ104⌬(Ϫ116/Ϫ100)). Analysis of ␤-galactosidase activity from this construct revealed a decrease in promoter activity to ϳ50% of the wild-type Ϫ134/ϩ104 construct (Fig. 8) . Furthermore, no difference in transcription was observed between vehicle and 1,25(OH) 2 D 3 treatment of cells transfected with the Ϫ133/ϩ104⌬(Ϫ116/Ϫ100) construct (Fig.  8) , demonstrating that PHEX proximal promoter repressibility is abolished when the Ϫ116 to Ϫ100 poly(A) element is deleted. The essentially identical results of suppressing basal activity and eliminating the 1,25(OH) 2 D 3 repressive effect, achieved with either deletion of the PHEX poly(A) element (Fig. 8) or overexpression of a dominant-negative VDR (Fig. 5B) , provide compelling evidence that 1,25(OH) 2 D 3 controls PHEX transcription via the poly(A) cis element, and likely does so by VDR-mediated attenuation of its uncharacterized 110 kDa transactivator.
DISCUSSION
The present results support and extend previous data suggesting that 1,25(OH) 2 D 3 suppresses the expression of PHEX in bone. Chronic exposure to 1,25(OH) 2 D 3 significantly represses PHEX transcription in cultured rat osteoblasts (Fig. 1 ) and mouse calvaria (data not shown), as well as mouse osteoblasts (21) and rat tibia (22) . The magnitude of this repression (35-75%) is indicative of pathophysiologic relevance because the disease phenotype of impaired skeletal mineralization in X-linked hypophosphatemia caused by an inactivating PHEX mutation is manifested in heterozygous females with a 50% decrease in PHEX expression (32) .
Temporally in osteoblasts (Fig. 1) is inhibition of mineralization of these bone cells (Fig. 2) . It may seem paradoxical that 1,25(OH) 2 D 3 would exert an antimineralization effect considering that vitamin D is recognized instead as an antirachitic principle. However, 1,25(OH) 2 D 3 is known to suppress Cbfa1, a gene involved in osteoblast development (33) , as well as repress ␣1 (I) collagen expression to limit bone matrix (34) . Moreover, knockout in mouse bone of either the genes encoding VDR (35) or osteocalcin (36), a bone remodeling protein induced by 1,25(OH) 2 D 3 , results in greater mineralized bone than in wild-type littermates. Therefore, although 1,25(OH) 2 D 3 -VDR promotes mineralization indirectly via stimulation of intestinal calcium and phosphate absorption, its direct affect on the mineralization process is counterintuitively negative. In other words, the role of 1,25(OH) 2 D 3 -VDR at the level of bone is to limit mineralization (Fig. 2, (21, 23) ). We propose that the mechanism whereby 1,25(OH) 2 D 3 curtails osteoblastic mineralization is via repression of PHEX, which in turn potentiates the antimineralization action of phosphatonin. (Fig. 4) is similar to the decrease in endogenous PHEX gene expression in UMR-106 cells (Fig. 1) and the in vivo decrease observed in rats (22) and mice, further suggesting similar regulation in vitro and in vivo. Moreover, this observed ϳ50% decrease in PHEX expression by 1,25(OH) 2 D 3 (Figs. 1, 4 (44) . Finally, as stated above, a 50% decrease in PHEX promoter activity elicited by 1,25(OH) 2 D 3 is in concert with a significant biologic effect, because the defective bone mineralization phenotype in XLH is manifest with mutation of only one of the two PHEX gene copies in heterozygous females (32) .
To date, we have been unable to locate in the scientific literature or in DNA sequence/transcription factor databases any description of a polyadenine-binding nuclear protein, much less one that has a molecular weight of ϳ110 kDa. We thus conclude that the protein which apparently mediates 1,25(OH) 2 D 3 control of PHEX is likely novel, and we have named it PHEX-activating protein 110 (PAP110). It should be noted that there is one newly recognized family of DNA-binding proteins that is perhaps the most closely related to PAP110, because members of this family bind mixed AT-rich DNA sequences. These proteins contain a novel DNA binding domain referred to as an AT-rich interacting domain (ARID), which is comprised of a series of six ␣-helices that contact both major and minor groove residues in an AAT(T/A)AA core hexamer consensus (45) . Members of the ARID protein family function in embryonic development, cell lineage gene regulation, and cell cycle control, and they mediate both positive and negative transcriptional control, likely involving modification of chromatin structure (46) . Recently, it has been revealed that several ARID proteins possess relaxed DNA binding specificity (45) , raising the possibility that PAP110 constitutes a unique member of the ARID family, or is at least related to this class of transcription factors in structure and/or function.
Considering the several potential modes of 1,25(OH) 2 D 3 -mediated down-regulation of gene expression, it is possible to integrate the current results into the framework of known negative actions of 1,25(OH) 2 D 3 to construct a hypothetical molecular mechanism for down-regulation of PHEX gene expression. We have demonstrated that 1,25(OH) 2 D 3 exposure or DNVDR expression (with or without 1,25(OH) 2 D 3 ) decreased PHEX promoter activity to identical levels (Fig. 5B) . It should be noted that the DNVDR utilized for these studies contains a mutation that abolishes its ability to transactivate (glutamic acid to alanine substitution at position 420, Ref. 27 ), but its ability to function in a repressive manner and to bind corepressors is unaffected. When considered together, these observations suggest an indirect mode of action, whereby VDR/RXR/ 1,25(OH) 2 D 3 interacts with a nVDRE on another gene that encodes an activator of PHEX gene expression. Furthermore, we show that a polyadenine region in the PHEX promoter is responsible for 1,25(OH) 2 D 3 mediated down-regulation and that this region specifically binds a novel 110 kDa nuclear protein (PAP110). We thus postulate that the most likely mechanism explaining these results would be for the gene encoding PAP110 to possess a nVDRE that is responsible for decreasing PAP110 protein expression with 1,25(OH) 2 D 3 exposure. This protein is presumed necessary for basal transcription of the PHEX gene, and when its expression is decreased (Figs. 6B and 7) or its binding is abolished by mutation of the 17 A-T base pair element (Fig. 8) , PHEX promoter activity decreases to subbasal levels. Thus, in the absence of 1,25(OH) 2 D 3 , osteoblastic PHEX expression is elevated because PAP110 is optimally expressed, and the result is phosphatonin destruction and bone mineralization. However, in the presence of either 1,25(OH) 2 D 3 and physiologic concentrations of VDR or overexpressed DNVDR, PAP110 is repressed, resulting in PHEX down-regulation, increased phosphatonin, and inhibition of osteoblastic mineralization.
